HELIUS MEDICAL TECHNOLOGIES INC
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
HSDT$1.83-4.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands, except share amounts)
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · Accumulated · · · | |||||||||||||||||
| · · · · Additional · · · · · Other · · · | |||||||||||||||||
| · · Class A Common Stock · · Paid-In · · Accumulated · · Comprehensive · · · | |||||||||||||||||
| · Shares · Amount · Capital · Deficit · Loss · Total | |||||||||||||||||
| Balance as of January 1, 2022 | | 75,570 | | $— | | $149,416 | | $(137,035) | | $(1,125) | | $11,256 | |||||
| Common stock issued under equity line of credit | | 7,827 | | | — | | | 644 | | | — | | | — | | | 644 |
| Issuance of common stock in public offering | | 480,000 | | | 1 | | | 8,055 | | | — | | | — | | | 8,056 |
| Share issuance costs | — | | — | | (758) | | — | | — | | (758) | ||||||
| Settlement of restricted stock units | 364 | | — | | — | | — | | — | | — | ||||||
| Common stock issued for services | 173 | | — | | 34 | | — | | — | | 34 | ||||||
| Stock-based compensation | 160 | | — | | 2,254 | | — | | — | | 2,254 | ||||||
| Other comprehensive gain | — | | — | | — | | — | | 737 | | 737 | ||||||
| Net loss | — | | — | | — | | (14,072) | | — | | (14,072) | ||||||
| Balance as of December 31, 2022 | 564,094 | | $1 | | $159,645 | | $(151,107) | | $(388) | | $8,151 | ||||||
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · Accumulated · · · | |||||||||||||||||
| · · · · Additional · · · · · Other · · · | |||||||||||||||||
| · · Class A Common Stock · · Paid-In · · Accumulated · · Comprehensive · · · | |||||||||||||||||
| · Shares · Amount · Capital · Deficit · Loss · Total | |||||||||||||||||
| Balance as of January 1, 2023 | | 564,094 | | $1 | | $159,645 | | $(151,107) | | $(388) | | $8,151 | |||||
| Issuance of common stock in public offering | | 53,010 | | | — | | | 500 | | | — | | | — | | | 500 |
| Share issuance costs | — | | | — | | | (65) | | | — | | | — | | | (65) | |
| Exercise of warrants | 92,910 | | — | | 1,270 | | — | | — | | 1,270 | ||||||
| Settlement of restricted stock units | 4,576 | | — | | — | | — | | — | | — | ||||||
| Stock-based compensation | — | | — | | 1,629 | | — | | — | | 1,629 | ||||||
| Other comprehensive loss | — | | — | | — | | — | | (285) | | (285) | ||||||
| Net loss | — | | — | | — | | (8,850) | | — | | (8,850) | ||||||
| Balance as of December 31, 2023 | 714,590 | | $1 | | $162,979 | | $(159,957) | | $(673) | | $2,350 | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.